calcium carbonate Side Effects
Also known as: Tums, Caltrate, Os-Cal
Analysis of 64,404 adverse event reports submitted to the FDA from 2002 to 2025.
Total Reports
64,404
Death-Related
8,716
13.5% of reports
Hospitalizations
27,035
42.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 8,716 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 2,195 |
| FATIGUE | 1,498 |
| OFF LABEL USE | 1,450 |
| HYPERTENSION | 1,443 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,430 |
| TYPE 2 DIABETES MELLITUS | 1,341 |
| RHEUMATOID ARTHRITIS | 1,338 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 1,335 |
| VOMITING | 1,322 |
| HYPOAESTHESIA | 1,309 |
| INFUSION RELATED REACTION | 1,298 |
| DYSPNOEA | 1,292 |
| GLOSSODYNIA | 1,277 |
| SWELLING | 1,277 |
| PSORIATIC ARTHROPATHY | 1,267 |
| RASH | 1,266 |
| HAND DEFORMITY | 1,256 |
| HEPATIC ENZYME INCREASED | 1,255 |
| CONDITION AGGRAVATED | 1,244 |
| PAIN | 1,241 |
Reactions in Hospitalization Reports
Top reactions in 27,035 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| NAUSEA | 3,166 |
| FATIGUE | 3,019 |
| VOMITING | 2,934 |
| DYSPNOEA | 2,836 |
| OFF LABEL USE | 2,809 |
| PNEUMONIA | 2,805 |
| DIARRHOEA | 2,743 |
| PAIN | 2,654 |
| PYREXIA | 2,508 |
| MALAISE | 2,341 |
| HEADACHE | 2,288 |
| ASTHENIA | 2,252 |
| DRUG INEFFECTIVE | 2,073 |
| CONDITION AGGRAVATED | 2,045 |
| ARTHRALGIA | 2,028 |
| HYPERTENSION | 2,028 |
| FALL | 1,963 |
| CONFUSIONAL STATE | 1,924 |
| DIZZINESS | 1,811 |
| RHEUMATOID ARTHRITIS | 1,750 |
Nearby — Related Medications
What the FAERS Data Reveals About calcium carbonate Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 64,404 voluntary reports linked to calcium carbonate and its brand equivalents (Tums, Caltrate, Os-Cal), spanning 2002 through 2025. Of those, 8,716 (13.5%) listed death as an outcome and 27,035 (42.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 67% were female and 33% male; age distribution skews toward 45-64, with 13,889 reports in that bracket. The single most reported reaction is fatigue with 6,169 submissions, followed by nausea and diarrhoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.